Summary
The systemic availability of glucagon and human calcitonin given intranasally to healthy volunteers as spray solutions or powders has been examined.
Glucagon was absorbed only when surfactants were used, and 9-lauryl ether (as a spray) and sodium glycocholate (as spray or powder) were equally active. Calcitonin was poorly absorbed when given alone but the surfactants dihydrofusinate (as spray or powder) and glycocholate (as a spray) were equally active in promoting absorption. Thus, enhancers are required to obtain significant nasal absorption of glucagon and calcitonin and powders and spray solutions did not differ in terms of systemic availability.
This is a preview of subscription content, log in via an institution to check access.
References
Pontiroli AE, Secchi A, Alberetto M (1985) Alternative routes of peptide hormone administration. Spec Top Endocrinol Metab 7: 77–99
Harris AS (1986) Biopharmaceutical aspects of the intranasal administration of peptides. In: Davis SS, Illum L, Tomlinson E (eds) Delivery systems for peptide drugs. NATO ASI Series 125. Plenum, New York, p 191
Pontiroli AE, Alberetto M, Pajetta E, Calderara A, Pozza G (1987) Human insulin plus sodium glycocholate in a nasal spray formulation: Improved bioavailability and effectiveness in normal subjects. Diabetes Metab 13: 441–443
Pontiroli AE, Alberetto M, Pozza G (1984) Metabolic effects of intranasally administered glucagon: Comparison with intra muscular and intravenous injection. Acta Diabetol Lat 22: 103–110
Pontiroli AE, Alberetto M, Pozza G (1985) Intranasal calcitonin and plasma calcium concentration in normal subjects. Br Med J 1: 1390
Reginster JY, Denis D, Albert A, Deroisy R, Lecart MP, Fontaine MA, Lambelin P, Franchimont P (1987) One-year controlled randomised trial of prevention of early post menopausal bone loss by intranasal calcitonin. Lancet 2: 1481–1483
Hirai S, Yashiki T, Mima H (1981) Mechanism for the enhancement of the nasal absorption of insulin by surfactants. Int J Pharm 9: 173–184
Morimoto K, Morisaka K, Kamada A (1985) Enhancement of nasal absorption of insulin and calcitonin using polyacrylic acid gel. J Pharm Pharmacol 37: 134–136
Duchateau GS, Zuidema J, Merkus F (1986) Bile salts and intranasal drug absorption. Int J Pharm 31: 193–199
Pontiroli AE, Alberetto M, Secchi A, Dossi G, Bosi I, Pozza G (1982) Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects. Br Med J 284: 303–306
Moses AC, Gordon GS, Carey MC, Flier JS (1983) Insulin administered intranasally as an insulin-bile salt aerosol. Effectiveness and reproducibility in normal and diabetic subjects. Diabetes 32: 1040–1047
Longenecker JP (1986) Nazlin transnasal systemic delivery of insulin. In: Davis SS, Illum L, Tomlinson E (eds) Delivery systems for peptide drugs. NATO ASI Series 125. Plenum New York, p 211
Salzman R, Manson JE, Griffing GT, Kimmerle R, Ruderman R, McCall A, Stoltz EI, Mullin C, Small D, Armstrong J, Melby JC (1985) Intranasal aerosolized insulin. N Engl J Med 312: 1078–1084
Buclin T, Randin JP, Jacquet AF, Azria M, Attinger M, Gomez F, Burkhardt P (1987) The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif Tissue Int 41: 252–258
Lee VHL (1986) Enzymatic barriers to peptide and protein absorption and the use of penetration enhancers to modify absorption. In: Davis SS, Illum L, Tomlinson E (eds). Delivery systems for peptide drugs. NATO ASI Series 125. Plenum, New York, p 87
Gordon GS, Moses AC, Silver RD, Flier JS, Carey MC (1985) Nasal absorption of insulin: Enhancement by hydrophobic bile salts. Proc Natl Acad Sci 82: 7419–7423
Moses AC, Flier JS (1987) Unconventional routes of insulin administration. In: Alberti KGMM, Krall LP (eds) Diabetes annual 3. Elsevier, Amsterdam, p 107
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pontiroli, A.E., Alberetto, M., Calderara, A. et al. Nasal administration of glucagon and human calcitonin to healthy subjects: a comparison of powders and spray solutions and of different enhancing agents. Eur J Clin Pharmacol 37, 427–430 (1989). https://doi.org/10.1007/BF00558516
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558516